{
    "clinical_study": {
        "@rank": "114198", 
        "acronym": "MAHI", 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess safety and device performance of the Medtronic\n      Hospital Glucose Management System (HGMS) for up to 72-hours."
        }, 
        "brief_title": "Feasibility Study to Evaluate Safety and Device Performance of the Hospital Glucose Management System (HGMS)", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Transient or Diabetes-related Hyperglycemia", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Hyperglycemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject is at least 18 years old\n\n          2. Subject is admitted to the ICU\n\n          3. Subject has a treatment regimen that includes a glucose target range of \u2265140 mg/dl\n\n          4. Subject has a treatment regimen that includes an intended continuous intravenous\n             insulin for at least 24 hours\n\n             a. Including patients with no previous diagnosis of Diabetes Mellitus\n\n          5. Subject has anticipated life expectancy greater than 96 hours\n\n          6. Subject has recent platelet count greater than 30,000 per micro-liter\n\n        Exclusion Criteria:\n\n          1. Subject currently has a suspected or diagnosed medical condition that, in the opinion\n             of the Investigator, warrants exclusion from the study or prevents the subject from\n             completing the study\n\n          2. Subject is currently participating in another investigational drug or device study\n\n          3. Subject is pregnant, as determined by hospital admission\n\n          4. Subject is receiving treatment that includes Hydroxyurea."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult patients admitted to the Intensive Care Unit (ICU) and on intravenous (IV) insulin\n        therapy for the treatment of transient or diabetes-related hyperglycemia"
            }
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01763567", 
            "org_study_id": "CEP244"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Medtronic", 
            "Diabetes", 
            "Hospital", 
            "Continuous Glucose Monitor", 
            "Intensive Care Unit"
        ], 
        "lastchanged_date": "January 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kansas City", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "64111"
                }, 
                "name": "St Luke's Hospital Mid America Heart Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multi-Phased, Multi-Center Study to Evaluate Safety and Device Performance of the Medtronic Hospital Glucose Management System (HGMS) in Critically Ill Adult Patients", 
        "overall_official": {
            "affiliation": "St Luke's Hospital Mid America Heart Institute", 
            "last_name": "Mikhail Kosiborod, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Moderate and severe anticipated device and procedure related adverse events\nAll serious adverse events and unanticipated adverse device effects related events", 
                "measure": "Safety", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Functionality of HGMS\nAccuracy\nAlarms Specificity and Sensitivity (providing there are sufficient points)", 
                "measure": "Device Performance", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01763567"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Medtronic Diabetes", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medtronic Diabetes", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2013"
    }
}